Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Dysfunctional HDL as a diagnostic and therapeutic target Smith JDArterioscler Thromb Vasc Biol 2010[Feb]; 30 (2): 151-5The atheroprotective effects of HDL are mediated by several mechanisms, including its role in reverse cholesterol transport and via its antiinflammatory properties. However, not all HDL is functionally similar. HDL and apolipoprotein A-I may become dysfunctional or even proinflammatory and thus promote atherosclerosis. ApoAI posttranslational modification can have a large impact on its function. Myeloperoxidase modification of apoAI impairs its function as a cholesterol acceptor, and the molecular changes induced by myeloperoxidase have been studied in detail. These studies provide the basis for the development of an oxidant-resistant form of apoAI and clinical measures of HDL modification and dysfunction, which may be useful as a treatment criterion.|Animals[MESH]|Apolipoprotein A-I/*metabolism[MESH]|Atherosclerosis/diagnosis/drug therapy/*metabolism[MESH]|Biomarkers/metabolism[MESH]|Cholesterol/metabolism[MESH]|Humans[MESH]|Hypolipidemic Agents/therapeutic use[MESH]|Inflammation/diagnosis/drug therapy/*metabolism[MESH]|Lipoproteins, HDL/*metabolism[MESH]|Peroxidase/metabolism[MESH]|Predictive Value of Tests[MESH]|Protein Conformation[MESH]|Protein Processing, Post-Translational[MESH]|Structure-Activity Relationship[MESH] |